DASH Prediction Score for Recurrent VTE
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
حداقل ۳ — حداکثر ۲۴ • واحد: months
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk-2–1
- Intermediate Risk2–2
- High Risk3–6
The DASH Prediction Score for Recurrent VTE calculates predicting likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Key inputs include d dimer positive. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.
Clinical Indication
The DASH Prediction Score for Recurrent VTE is indicated for bedside clinical practice to support Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Excludes VTE during pregnancy, puerperium, trauma, surgery, immobilization, or active cancer.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Original validation used vitamin K antagonists.
DASH Score = (+2 if D-dimer positive) + (+1 if age ≤50 years) + (+1 if male) + (-2 if hormonal therapy in women)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| d_dimer_positive | string | Yes | Post-anticoagulation D-dimer result (measured approximately 1 month after stopping anticoagulation) |
| age | integer | Yes | Patient age in years(years) |
| sex | string | Yes | Patient biological sex |
| hormonal_therapy | string | Yes | Hormonal therapy use at time of initial VTE (applies to women only, select 'not_applicable' for men) |
| vte_type | string | No | Type of initial venous thromboembolism for clinical context |
| anticoagulation_duration | integer | No | Duration of initial anticoagulation treatment in months(months) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| -2–1 | Low Risk | Low annual recurrence risk |
| 2–2 | Intermediate Risk | Moderate annual recurrence risk |
| 3–6 | High Risk | High annual recurrence risk |
Evidence-Based References (EBM)
- Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019-1025. doi: 10.1111/j.1538-7836.2012.04735.x.DOI: 10.1111/j.1538-7836.2012.04735.x
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.DOI: 10.1016/j.chest.2015.11.026
- Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830.DOI: 10.1182/bloodadvances.2020001830
- Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636. doi: 10.1161/CIRCULATIONAHA.109.925214.DOI: 10.1161/CIRCULATIONAHA.109.925214